Enliven Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2021 | $-46.8M | $-46.8M | $12.0K | $3.8M |
| FY2022 | $-32.1M | $-32.7M | $612.0K | $3.2M |
| FY2023 | $-61.3M | $-61.4M | $149.0K | $12.9M |
| FY2024 | $-73.2M | $-73.2M | $44.0K | $20.2M |
| FY2025 | $-70.3M | $-70.5M | $158.0K | $34.0M |